Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Insulet Corporation

Market Cap 9.63B 8.46B 7.79B 7.29B 13.68B 912B 13.92B 93.67B 36.18B 447B 36.13B 35.35B 1,555B P/E 2026 *
23.1x
P/E 2027 * 18x
Enterprise Value 9.73B 8.55B 7.88B 7.37B 13.82B 921B 14.06B 94.65B 36.55B 452B 36.51B 35.72B 1,572B EV / Sales 2026 *
2.93x
EV / Sales 2027 * 2.37x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+3.55%
1 week-2.86%
Current month-0.72%
1 month-7.08%
3 months-36.64%
6 months-50.65%
Current year-49.37%
1 week 138.79
Extreme 138.79
150.82
1 month 138.79
Extreme 138.79
161.35
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
06-02Buy

Director

2,790 0.0040%
06-02Sell

Director

-418 0.0006%
06-02Buy

Director

3,450 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
+3.55%-2.86%-52.53%-50.62% 9.63B
+3.07%+2.10%-31.93%-16.37% 153B
+1.72%+0.31%-6.61%-7.76% 101B
-1.82%-0.54%+56.86%+55.61% 55.9B
+3.62%-0.12%-4.28%+49.62% 52.78B
+2.28%-1.10%-14.55%-44.23% 38.77B
+1.70%-5.44% - - 29.35B
-0.22%-7.14%-13.85%-45.53% 26.65B
+2.03%+1.50%+55.87%-8.76% 23.29B
-2.25%-1.92%-16.37%-5.76% 20.51B
Average +1.37%-2.75%-3.04%-8.20% 51.13B
Weighted average by Cap. +1.76%-1.86%-6.38%-2.70%

Financials

2026 *2027 *
Net sales 3.32B 2.92B 2.69B 2.52B 4.72B 315B 4.8B 32.34B 12.49B 154B 12.48B 12.21B 537B 3.94B 3.46B 3.19B 2.98B 5.59B 373B 5.69B 38.32B 14.8B 183B 14.78B 14.46B 636B
Net income 435M 382M 352M 329M 617M 41.17B 628M 4.23B 1.63B 20.19B 1.63B 1.6B 70.22B 566M 497M 458M 429M 804M 53.61B 818M 5.51B 2.13B 26.3B 2.12B 2.08B 91.45B
Net Debt 101M 88.45M 81.5M 76.26M 143M 9.53B 146M 980M 378M 4.68B 378M 370M 16.26B -285M -250M -231M -216M -405M -26.97B -412M -2.77B -1.07B -13.23B -1.07B -1.05B -46.01B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-06-23 US$143.90 +3.55% 1,852,502
26-06-22 US$138.97 -4.66% 1,685,321
26-06-18 US$145.76 +1.56% 2,864,144
26-06-17 US$143.52 -2.82% 1,542,221
26-06-16 US$147.69 -0.30% 942,276
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
138.97USD
Average target price
240.25USD
Spread / Average Target
+72.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!